Microecology and Immunity in Patients With Anti-MDA5 Antibody Positive Dermatomyositis and Interstitial Lung Disease
Recruiting · NCT06203249 · Observational (researchers observe without assigning treatment) · Lead sponsor: Chinese PLA General Hospital
View the official record on ClinicalTrials.gov →What this trial is about
The purpose of this study was to analyze the relationship between the microbial community, host immunity and the presence or absence of concurrent rapidly progressive interstitial lung disease patients with anti-MDA5 antibody positive dermatomyositis.
Who can take part
Age range
18 Years to 100 Years
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not specified
Study type
Observational (researchers observe without assigning treatment)
Inclusion criteria
- Patients who meet the diagnostic criteria of dermatomyositis and anti-MDA 5 antibody positive.
- Anti-MDA5 antibody positive DM patients with RPILD meet the diagnostic criteria for RPILD.
- Must have undergone bronchoalveolar lavage.
- Age≥18 years old.
- Patients who signed informed consent forms
Exclusion criteria
- Patients who had other connective tissue diseases.
- Patients with ILD or RPILD caused by infection, tumors, drugs, biochemistry and other factors.
- Pregnant or lactating patients.
- The patient also participated in any other clinical trial.
- Disagreement for inclusion in this study
Where it is running
1 location listed.
Read the full protocol, contacts and eligibility on ClinicalTrials.gov →